[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Oftalmología Fundación Conde de Valenciana\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":238},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,75,102,148,178,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644483","phase-2-safety-and-efficacy-of-topical-infliximab-in-autoimmune-dry-eye-disease-100644483",false,"NCT07671222","Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease","Safety and Efficacy of Topical Infliximab Versus Topical Steroid in Autoimmune Dry Eye Disease: Randomized Controlled Trial.","INFLIXIDRY","Inclusion Criteria:\n\n* Adult patients (≥ 18 years).\n* Confirmed diagnosis of primary or secondary Sjögren's syndrome according to the 2016 ACR\u002FEULAR classification criteria.\n* On stable systemic immunomodulatory therapy (non-biologic) for at least 12 weeks, with no planned changes during the study (see section 14.1 if there are concerns about confounding variables).\n* Negative chest X-ray or Interferon-Gamma Release Assays (IGRA).\n* Diagnosis of severe dry eye, defined by meeting all of the following criteria in at least one eye at study entry:\n* OSS (SICCA 0-12) ≥ 6 in at least one eye.\n* OSDI ≥ 33 (severe symptoms).\n* Symptoms: OSDI score ≥ 33.\n* Signs: Ocular Staining Score (OSS, SICCA) ≥ 6.\n* Ability to understand and sign informed consent and to comply with study procedures and treatment administration.\n\nExclusion Criteria:\n\n* Current use of topical corticosteroids or topical immunomodulators (cyclosporine, lifitegrast, tacrolimus, autologous serum) within 30 days prior to enrollment.\n* Current or recent use (\\\u003C 3 months) of punctal plugs.\n* Active ocular infection (bacterial, viral, fungal) or recent history of herpetic keratitis.\n* Ocular or eyelid surgery within the past 6 months.\n* Use of contact lenses during the study period.\n* Known allergy or hypersensitivity to infliximab, murine proteins, or any component of the formulation (including CMC).\n* Coexisting ocular conditions that may interfere with dry eye evaluation (e.g., active ocular cicatricial pemphigoid, active ocular graft-versus-host disease, uncontrolled glaucoma, significant corneal dystrophy).\n* Systemic conditions considered contraindications to infliximab exposure, including: active systemic infection, untreated active or latent tuberculosis, history of demyelinating disease, moderate to severe congestive heart failure (NYHA Class III\u002FIV), or history of malignancy within the past 5 years.\n* Use of systemic biologic agents within the past 6 months (12 months for systemic anti-TNF-α therapy).\n* Pregnancy, breastfeeding, or intention to become pregnant during the study.\n* Participation in another clinical trial with an investigational drug within the past 30 days.\n* Ability to understand and sign informed consent and to comply with study procedures and treatment administration.","ALL","18 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Sjögren's syndrome is a condition in which the immune system attacks the body's moisture-producing glands. This often causes severe dry eye, leading to discomfort, irritation, blurred vision, and damage to the eye surface. Inflammation plays an important role in this process, and a protein called TNF-alpha is one of the key drivers.\n\nThis study will test a new eye drop containing infliximab, a medication that blocks TNF-alpha. The goal is to see whether this treatment can safely improve symptoms and signs of severe dry eye in patients with Sjögren's syndrome.",[27,28,29],"Sjogren Syndrome","Sjogren Syndrome With Keratoconjunctivitis","Dry Eye Disease (DED)",[31,32,33,34],"Dry eye disease","Sjogren syndrome","Sjogren disease","Autoimmune dry eye","NOT_YET_RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":21},"2026-12",{"date":43,"type":21},"2028-03",{"name":45,"class":46},"Instituto de Oftalmología Fundación Conde de Valenciana","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100622739","phase-4-the-effectiveness-of-topical-silicone-application-combined-with-photoprotection-in-the-development-of-scarring-following-blepharoplasty-100622739","NCT07387536","The Effectiveness of Topical Silicone Application Combined With Photoprotection in the Development of Scarring Following Blepharoplasty","ETSACPDSFP","Inclusion Criteria:\n\n* The study participants are individuals aged 18 years and older, encompassing both male and female subjects. These participants are undergoing blepharoplasty and have provided their written informed consent to partake in the research.\n\nExclusion Criteria:\n\n* Individuals with a history of previous surgical procedures on the eyelids, apart from the current blepharoplasty. . Those who have previously undergone intralesional modulation are also considered. Individuals with a known allergy to any components of the product under investigation. The presence of local skin infections in the treatment area. Suspicious skin lesions suggestive of malignancy in the eyelid region. Pregnancy or breastfeeding during the study. - Research subjects who, after being included in the study, do not complete the scheduled clinical follow-up. Research subjects who discontinue the use of the topical treatment before the end of the established period. Voluntary withdrawal of informed consent at any stage of the study. Later detection of exclusion criteria that were not identified during the initial evaluation.",{"count":56,"type":21},30,[58],"PHASE4","Assess the efficacy of utilizing topical silicone with photoprotection (Improscar Stick® 50) on the quality of healing following upper blepharoplasty, employing the Vancouver and POSAS scales (both patient and observer) over a minimum follow-up period of three months.",[61],"Scar Formation",[63,64,65],"Upper Blepharoplasty Approach","Post-operative Scar","Vancouver Scar Scale","RECRUITING","2026-01-28",{"date":69,"type":39},"2026-02-04",{"date":71,"type":39},"2025-10-01",{"date":73,"type":21},"2026-05-31",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100621863","phase-4-fractional-co2-laser-assisted-delivery-of-hyaluronic-acid-ascorbic-acid-and-sodium-dna-for-enhancing-facial-skin-quality-in-individuals-over-the-age-of-30-100621863","NCT07376148","Fractional CO2 Laser-assisted Delivery of Hyaluronic Acid, Ascorbic Acid and Sodium DNA For Enhancing Facial Skin Quality in Individuals Over the Age of 30","FCLADHAAASDFSQ","Inclusion Criteria:\n\n* Male and female subjects, over 30 years of age, with moderate skin changes associated with elasticity, wrinkles, roughness, pigmentation, erythema, and pore size; with at least 12 points on the SASSQ scale. Fitzpatrick skin type I-III. Participants who agree to take part in the protocol\n\nExclusion Criteria:\n\n* Fitzpatrick skin type IV-VI. Local infections or inflammatory disorders.. Neoplasms suspected of being malignant. Allergy to hyaluronic acid, ascorbic acid, and sodium DNA. Hypersensitivity to fractional CO2 laser. Pregnancy or breastfeeding. Local or systemic adverse reaction","30 Years",{"count":56,"type":21},[58],"Evaluate the effectiveness of topical hyaluronic acid, ascorbic acid, and sodium DNA following ablative fractional laser treatment in objectively reversing facial skin alterations induced by photoaging.",[87,88,89],"Skin Quality Improvement","Photo-aged Skin","Drug Delivery Systems",[91,92,93],"Skin Quality","Fractional Ablative Resurfacing;","Topical Drugs","2026-01-21",{"date":96,"type":39},"2026-01-29",{"date":98,"type":39},"2025-11-07",{"date":100,"type":21},"2026-04-30",{"name":45,"class":46},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":47},"100621614","protect-corneal-wavefront-guided-prk--epi-off-cxl-vs-ptkepi-off-cxl-in-keratoconus-100621614","NCT07372911","PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus","Corneal Wavefront Guided PRK Combined With Epi-off Corneal Cross-Linking Versus Epi-off Corneal Cross-Linking With PTK Epithelial Removal in Keratoconus: A Randomized Clinical Trial","PRoTECT","Inclusion Criteria:\n\n* Age 18-40 years\n* Diagnosis of keratoconus, ABCD Belin stage I-III at baseline\n* Minimum (thinnest) corneal pachymetry ≥ 450 µm pre-op\n* Written informed consent\n* Age-stratified progression requirements:\n* 18-25 y: keratoconus stage I-III (progression not mandatory)\n* 25-35 y: documented progression (meet ≥ 2 Table-1 criteria below) or, if recent documentation is absent, high-risk features for future progression: Kmax \\> 53 D, strong family history, severe atopy with persistent eye rubbing, or any of the following over 12 months: ΔKmax ≥ 1.0 D, thinnest pachymetry decrease ≥ 10 µm, or increase in manifest cylinder ≥ 1.0 D\n* 35-40 y: clear, unequivocal recent progression (meet ≥ 2 Table-1 criteria); late-onset documented progression may be considered\n\nExclusion Criteria:\n\n* Central corneal scars or opacities\n* Prior ocular surgery or trauma (exception: prior LASIK if it is the cause of post-surgical ectasia, per protocol text)\n* Autoimmune disease or uncontrolled diabetes mellitus\n* Pregnancy or lactation\n* Contact lens wear within 2 weeks before baseline evaluation",{"count":111,"type":21},50,[113],"NA","Keratoconus causes irregular astigmatism and reduced vision. Epi-off corneal crosslinking (CXL) stabilizes the cornea but often leaves higher-order aberrations uncorrected. This randomized, parallel-group trial compares corneal wavefront guided photorefractive keratectomy (corneal wavefront guided PRK, 50 µm therapeutic ablation) combined with accelerated epi-off CXL versus epi-off CXL with epithelial removal by phototherapeutic keratectomy (PTK) using a Schwind AMARIS excimer laser, in adults with keratoconus. The primary endpoint is change in best-corrected distance visual acuity (logMAR) at 12 months. Key secondary endpoints include Kmax, corneal higher-order aberrations, manifest refraction, Scheimpflug densitometry (haze) and Fantes grade, Corvis ST biomechanics, NEI VFQ-25, and endothelial cell density by non-contact specular microscopy at 1, 3, 6 and 12 months.",[116],"Keratoconus",[116,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140],"Corneal ectasia","Corneal cross-linking","Corneal collagen crosslinking (CXL)","Epi-off CXL","Riboflavin UV-A","Topography-guided PRK","TG-PRK","Phototherapeutic keratectomy (PTK)","PTK epithelial removal","Schwind AMARIS excimer laser","Excimer laser","Athens Protocol (TG-PRK + CXL)","Crete protocol (PTK + CXL)","Pentacam Scheimpflug tomography","Kmax","Higher-order aberrations (HOAs)","Corneal haze","Specular microscopy","Endothelial cell density","NEI VFQ-25","Visual acuity (logMAR)","Randomized clinical trial","Parallel assignment","2026-01-20",{"date":67,"type":39},{"date":144,"type":39},"2025-09-01",{"date":146,"type":21},"2027-12-30",{"name":45,"class":46},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":17,"minAge":157,"maxAge":82,"enrollmentInfo":158,"targetDuration":160,"studyType":161,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":47},"100606112","treg-effector-function-and-th2treg-ratio-in-allergic-conjunctivitis-effect-of-desensitization-therapy-100606112","NCT07171307","Treg Effector Function and Th2\u002FTreg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy","Study of the Effector Function of Regulatory T Cells and the Th2\u002FTreg in Patients With Allergic Conjunctivitis With and Without Desensitization Treatment","INMUNOREG","Inclusion Criteria:\n\n* Subjects aged between 5 and 30 years, of either sex.\n* Subjects with a confirmed diagnosis of allergic conjunctivitis.\n* Presence of active symptoms.\n* Positive skin tests.\n* Willingness to participate in the protocol by signing informed consent.\n\nExclusion Criteria:\n\n* Subjects who have had an infection within the two months prior to sample collection.\n* Patients with other active systemic allergic diseases (such as bronchial asthma, dermatitis, among others).\n* Subjects with chronic-degenerative or autoimmune diseases.\n* Subjects who have received topical immunosuppressive treatment in the last two months.\n* Subjects receiving systemic immunosuppressive therapy.",true,"5 Years",{"count":159,"type":21},60,"1 Day","OBSERVATIONAL","This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2\u002FTreg ratio, in patients with allergic conjunctivitis with and without desensitization therapy, compared to healthy controls.\n\nPeripheral blood and tear samples will be collected once at enrollment. Treg and Th2 populations will be immunophenotyped, TIGIT and PD-1 expression assessed, and functional assays performed. Cytokine and antibody (IgE, IgG4) concentrations will be measured in serum and tears.\n\nResults will be analyzed using descriptive statistics, Shapiro-Wilk test for distribution, t-tests or ANOVA for group comparisons, and correlation analyses for associations, with p\\\u003C0.05 considered significant. This study seeks to identify immunological markers associated with disease severity and treatment response, potentially informing future therapeutic strategies.",[164],"Conjunctivitis, Allergic",[166,167,168,169],"conjunctivitis allergic","TIGIT","Tregs","PDL-1","2025-09-15",{"date":172,"type":39},"2025-09-17",{"date":174,"type":21},"2026-01-01",{"date":176,"type":21},"2026-09",{"name":45,"class":46},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":161,"phases":4,"briefSummary":188,"conditions":189,"keywords":196,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":47},"100606672","clinical-determinants-and-adverse-reactions-to-tropicamidephenylephrine-in-hospitalized-patients-100606672","NCT07178600","Clinical Determinants and Adverse Reactions to Tropicamide\u002FPhenylephrine in Hospitalized Patients.","Characterization and Association of Clinical Determinants With the Occurrence of Adverse Drug Reactions Following the Administration of Tropicamide\u002FPhenylephrine in Hospitalized Patients.","RAM-TF-IOCV","Inclusion Criteria:\n\n* Patients who have authorized participation in the study by signing informed consent.\n* Patients over 18 years of age.\n* Any sex.\n* Patients from the \"Instituto de Oftalmología Conde de Valenciana, IAP., sede Centro\" who have been scheduled for a surgical procedure.\n* Patients for whom the administration of two drops of tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL is indicated.\n* Patients that presents any type of disease\n\nExclusion Criteria:\n\n* Allergy to any component of the formulation.",{"count":187,"type":21},1000,"To evaluate the association between clinical determinants and the occurrence of adverse drug reactions in hospitalized patients who received tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL.\n\nAn ambispective, interventional, longitudinal study will be conducted to actively identify adverse reactions to tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL, as well as the clinical determinants that may predispose patients to the occurrence of an adverse drug reaction (ADR). Data will be collected through the administration of a questionnaire and measurement of vital signs prior to the administration of tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL, and subsequently at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours after administration, with the aim of establishing an association between these variables.",[190,191,192,193,194,195],"Adverse Drug Effect","Phenylephrine","Hypertension","Cardiovascular Complication","Ophthalmology","Ocular Discomfort",[190,197,198,199,200,192,194,201],"Tropicamide\u002Fphenylefrine","Tropicamide","Phenylefrine","Cardiovascular complications","Ocular discomfort","2025-09-11",{"date":172,"type":39},{"date":205,"type":39},"2023-09-02",{"date":176,"type":21},{"name":45,"class":46},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":156,"sex":17,"minAge":216,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":226,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":47},"100532933","intraoperative-aberrometry-vs-conventional-intraocular-lens-calculation-a-prospective-study-100532933","NCT06219252","Intraoperative Aberrometry vs Conventional Intraocular Lens Calculation, a Prospective Study.","Intraoperative Aberrometry vs Conventional Introcular Lens Calculation ( Barrett Universal II \u002F Barrett True K ), Refractive and Visual Outcomes, a Prospective Study.","ORAVSCTRL","Inclusion Criteria:\n\n* patients with senile cataract, patients undergoing phacoemulsification, complete biometric profile, axial length calculated by interferometer.\n\nExclusion Criteria:\n\n* glaucoma, uncontrolled diabetic retinopathy, pseudoexfoliation syndrome, aged macular degeneration , dry eye syndrome, other ocular pathologies.","40 Years",{"count":218,"type":21},300,[113],"the goal of this intervention study is to compare prospectively the accuracy of the power calculation between both groups, the intraoperative aberrometry (ORA) vs barrett universal II preoperative calculation (control group) .\n\nResearchers will compare ORA group vs control to see changes in spherical equivalent and uncorrected distance visual acuity",[222,223,224,225],"Intraocular Lens Implantation","Cataract","Humans","Ocular, Refraction",[227,228,229],"biometry","aberrometry","prospective study","2025-05-09",{"date":232,"type":39},"2025-05-14",{"date":234,"type":39},"2023-11-03",{"date":236,"type":21},"2026-12-31",{"name":45,"class":46},""]